Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- ESC Heart Failure 2025
Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF
João Pedro Ferreira, MD, PhD
Stephen J. Greene, MD
- ESC Heart Failure 2025
Effects of dapaglifozin on QoL and functional status in elderly TAVI patients with aortic stenosis
Clara Bonanad Lozano, MD, PhD
Varun Sundaram, MD, PhD
